Estuary launches with $103M for kidney disease gene therapies
What's the deal? Estuary BiotherapeuticsDealroom has a profile for this one. Try Dealroom → launched on Friday with $103 million to advance two preclinical gene therapy candidates targeting the most common type of kidney disease.
What's the endgame? The company aims to move its two candidates toward the clinic. Both remain at the preclinical stage.
The signal: Estuary's debut adds to continued investor appetite for cell and gene therapy startups tackling hard-to-treat diseases.
Read more: endpoints.news
Image credit: Generated with Gemini
